By Kathleen Gallagher of the Journal Sentinel
Nearly 10 years ago, Bradley Glenn, a Green Bay doctor, saw a need for a less-invasive way to deliver chemotherapy, antibiotics and nutrients to his patients.
His solution has become the core of a small Wisconsin start-up that is aiming to deliver a big payday to investors.
Stealth Therapeutics Inc. on Tuesday will begin a trial at two Wisconsin health care organizations to determine the best potential market for the company's Invisiport, a vascular access port that is implanted under the skin in a patient's arm.
"Our goal is to use the results from the study to ramp up use of the Invisiport throughout the country," said Sam Adams, Stealth's general manager. "Future commercial success will help us to create a return for our shareholders."
In essence, the study is intended to show potential acquirers how much value the device could add to their product mix, said Ken Johnson, a director of Stealth and the managing director of Kegonsa Capital Partners. Kegonsa is a major investor in Stealth, which has raised a total of $3.35 million, Adams said.